Home » Stocks » BGNE

BeiGene Ltd. (BGNE)

Stock Price: $312.19 USD -0.52 (-0.17%)
Updated Jul 29, 2021 4:00 PM EDT - Market closed
After-hours: $312.10 -0.09 (-0.03%) Jul 29, 6:42 PM
Market Cap 31.96B
Revenue (ttm) 862.69M
Net Income (ttm) -1.17B
Shares Out 92.38M
EPS (ttm) -13.47
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 29
Last Price $312.19
Previous Close $312.71
Change ($) -0.52
Change (%) -0.17%
Day's Open 315.24
Day's Range 300.63 - 315.24
Day's Volume 305,048
52-Week Range 205.29 - 388.97

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

CAMBRIDGE, Mass. & BEIJING, China--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global, science-driven biotechnology company, today announced positive topline results fr...

11 hours ago - Business Wire

A regulatory filing gave a sneak peek at the company's second-quarter sales.

1 day ago - The Motley Fool

Health Canada has approved BeiGene Ltd (NASDAQ: BGNE) Brukinsa (zanubrutinib) for the treatment of mantle cell lymphoma (MCL) in adult patients who have received at least one prior therapy. This is the ...

3 days ago - Benzinga

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global, science-driven biotechnology company focused on developing innovative and affordable med...

4 days ago - Business Wire

The China National Medical Products Administration (NMPA) has conditionally approved Kyprolis (carfilzomib) for relapsed or refractory (R/R) multiple myeloma. The approval covers Kyprolis in combination...

Other stocks mentioned: AMGN
3 weeks ago - Benzinga

BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene Announces the Approval in China of KYPROLIS® (Carfilzomib) for Injection for Adult Patients with Relapsed or Refractory Multiple Myeloma

3 weeks ago - Business Wire

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene Announces Acceptance of a Supplemental Biologics License Application in China for Tislelizumab in Esophageal Squamous Cell Carcinoma ...

3 weeks ago - Business Wire

PureTech Health plc (NASDAQ: PRTC) has announced a clinical trial and supply agreement with an affiliate of BeiGene Ltd (NASDAQ: BGNE). The partnership will evaluate BeiGene's tislelizumab, in combinati...

Other stocks mentioned: PRTC
3 weeks ago - Benzinga

BOSTON--(BUSINESS WIRE)--PureTech Announces Clinical Trial & Supply Agreement with BeiGene to Evaluate LYT-200 & Tislelizumab in Patients with Difficult-to-Treat Solid Tumors

Other stocks mentioned: PRTC
3 weeks ago - Business Wire

The pharmaceutical company had a solid first quarter and boasts a nice pipeline.

1 month ago - The Motley Fool

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines worl...

1 month ago - Business Wire

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines worl...

1 month ago - Business Wire

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines worl...

1 month ago - Business Wire

BeiGene Ltd (NASDAQ: BGNE) revealed an interim analysis of the Phase 3 ALPINE trial evaluating Brukinsa (zanubrutinib) to Johnson & Johnson's (NYSE: JNJ) Imbruvica (ibrutinib) for relapsed or refractory...

1 month ago - Benzinga

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines worl...

1 month ago - Business Wire

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines worl...

1 month ago - Business Wire

Shoreline Biosciences Inc and BeiGene Ltd (NASDAQ: BGNE) have announced an exclusive worldwide strategic collaboration to develop and commercialize a portfolio of NK-based cell therapeutics with Shoreli...

1 month ago - Benzinga

SAN DIEGO & CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--Shoreline Biosciences, Inc., a biotechnology company developing intelligently designed allogeneic off-the-shelf, standardized and...

1 month ago - Business Wire

BEIJING, China & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicin...

1 month ago - Business Wire

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines worl...

1 month ago - Business Wire

SHANGHAI, June 3, 2021 /PRNewswire/ -- Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), a healthcare services company offering online healthcare information, professional training and educa...

Other stocks mentioned: ZCMD
1 month ago - PRNewsWire

BeiGene CEO on Covid Collaborations, Regulation, China

YouTube video

Jun.02 -- John Oyler, co-founder, chief executive officer and chairman at BeiGene Ltd., a global pharmaceutical and biotechnology company, discusses the company's partnerships on covid therapies, global...

1 month ago - Bloomberg Markets and Finance

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene's ALPINE trial of BRUKINSA (zanubrutinib) versus ibrutinib in chronic lymphocytic leukemia will be featured in EHA2021 Presidential S...

1 month ago - Business Wire

BeiGene Ltd (NASDAQ: BGNE) has announced topline results from the Phase 3 RATIONALE 309 trial evaluating tislelizumab combined with chemotherapy as a first-line treatment of recurrent or metastatic naso...

2 months ago - Benzinga

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines worl...

2 months ago - Business Wire

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines worl...

2 months ago - Business Wire

The FDA has accepted for review BeiGene Ltd's (NASDAQ: BGNE) supplemental marketing application for Brukinsa (zanubrutinib) for marginal zone lymphoma (MZL) and granted priority review. The application ...

2 months ago - Benzinga

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines worl...

2 months ago - Business Wire

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines worl...

2 months ago - Business Wire

BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines worl...

2 months ago - Business Wire

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene reported recent business highlights, anticipated upcoming milestones, and financial results for the first quarter of 2021.

2 months ago - Business Wire

BeiGene Ltd (NASDAQ: BGNE) announced positive results from a planned interim analysis of the Phase 3 ALPINE trial comparing Brukinsa (zanubrutinib) against Johnson & Johnson's (NYSE: JNJ) Imbruvica (ibr...

Other stocks mentioned: JNJ
3 months ago - Benzinga

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)--BeiGene announces positive interim results in Phase 3 ALPINE trial comparing BRUKINSA® (zanubrutinib) to ibrutinib in chronic lymphocytic leukemia.

3 months ago - Business Wire

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medi...

3 months ago - Business Wire

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medi...

3 months ago - Business Wire

BeiGene Ltd (NASDAQ: BGNE) has announced data from Phase 2 trial evaluating Brukinsa (zanubrutinib) in hospitalized COVID-19 patients, requiring supplemental oxygen without mechanical ventilation. The s...

3 months ago - Benzinga

MISSISSAUGA, Ontario--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines ...

3 months ago - Business Wire

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines worl...

3 months ago - Business Wire

BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medi...

3 months ago - Business Wire

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines, tod...

3 months ago - Business Wire

Investors often look to top fund managers to glean information on the best strategies and generate new investment ideas.

Other stocks mentioned: ABNB, ASML, CYH, GS, SEAS, SIEN
4 months ago - GuruFocus

In Amgen Inc.'s (NASDAQ:AMGN) recent agreement to buy small cancer drug developer Five Prime Therapeutics Inc. (NASDAQ:FPRX) for nearly $2 billion, there seems to be a message for investors in other sma...

Other stocks mentioned: AMGN, BMY, FPRX
4 months ago - GuruFocus

Hutchison China MediTech (NASDAQ: HCM) has initiated a Phase 1b/2 study of surufatinib combined with BeiGene Ltd's (NASDAQ: BGNE) tislelizumab in patients with advanced solid tumors in the U.S. and Euro...

Other stocks mentioned: HCM
4 months ago - Benzinga

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene Announces Presentation of Clinical and Preclinical Data at the AACR Annual Meeting 2021

4 months ago - Business Wire

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medi...

4 months ago - Business Wire

With the trading day about halfway over, the broad markets were pushing higher on the day.

Other stocks mentioned: BMBL, NEE, WPM, AKBA, ARAV, IMO, IOVA ...
4 months ago - 24/7 Wall Street

BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medi...

4 months ago - Business Wire

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--Health Canada Approves BRUKINSA® (Zanubrutinib) for the Treatment of Waldenström's Macroglobulinemia

4 months ago - Business Wire

The stock price of BeiGene, a biotechnology company focused on developing molecularly targeted and immuno-oncology drug candidates, has seen a 10% drop over the last ten trading days, while it's down 6%...

5 months ago - Forbes

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene Announces Closing of Collaboration with Novartis to Develop & Commercialize Anti-PD-1 Antibody Tislelizumab in North America, Europe ...

5 months ago - Business Wire

About BGNE

BeiGene, Ltd. discovers, develops, manufactures, and commercializes medicines for cancer therapeutics in the People's Republic of China and the United States. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; ABRAXANE to treat breast cancer; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblast... [Read more...]

Industry
Biotechnology
IPO Date
Feb 3, 2016
CEO
John Oyler
Employees
5,400
Stock Exchange
NASDAQ
Ticker Symbol
BGNE
Full Company Profile

Financial Performance

In 2020, BeiGene's revenue was $308.87 million, a decrease of -27.87% compared to the previous year's $428.21 million. Losses were -$1.60 billion, 68.3% more than in 2019.

Financial Statements

Analyst Forecasts

According to 17 analysts, the average rating for BeiGene stock is "Buy." The 12-month stock price forecast is 374.00, which is an increase of 19.80% from the latest price.

Price Target
$374.00
(19.80% upside)
Analyst Consensus: Buy